Protocol Details

Cancer Risk in Xeroderma Pigmentosum Heterozygotes

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	02-C-0313
Sponsoring Institute	National Cancer Institute (NCI)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: N/A Max Age: N/A
Referral Letter Required	No
Population Exclusion(s)	None
Special Instructions	Currently Not Provided
Keywords	DNA Repair; Molecular Epidemiology; Skin Cancer; Genetics; Melanoma
Recruitment Keyword(s)	Xeroderma Pigmentosum; XP
Condition(s)	Xeroderma Pigmentosum
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Cancer Institute

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers.

Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease.

XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects.

Patients and their family members will undergo some or all of the following procedures:

- Parental permission to review the child's relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses

- Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations

- Photographs to document skin and other physical findings

- Nuclear medicine scans to evaluate the brain and nervous system

- X-rays of the skull or other parts of the body

- Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement

- Collection of blood and skin samples for gene studies

- Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies.

- Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope

- Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek

- Collection of a hair sample for microscopic examination and composition analysis

- Surgery to treat skin cancers or other lesions

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age, gender or race are eligible for this study.

On referral, families of XP patients will be considered for inclusion in the study if the proband has clinical documentation of features of XP and laboratory determination of the DNA repair defect. All relatives of XP patients including spouses are eligible to participate.

EXCLUSION CRITERIA:

Inability or unwillingness to provide family history information or tissue (skin, blood, buccal cells or hair) for laboratory studies.

--Back to Top--

Citations:

[No authors listed] Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996 May;14(5):1730-6; discussion 1737-40.

Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 1998 Apr 1;58(7):1376-9.

Cheo DL, Meira LB, Burns DK, Reis AM, Issac T, Friedberg EC. Ultraviolet B radiation-induced skin cancer in mice defective in the Xpc, Trp53, and Apex (HAP1) genes: genotype-specific effects on cancer predisposition and pathology of tumors. Cancer Res. 2000 Mar 15;60(6):1580-4.

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
Kenneth H. Kraemer, M.D. National Cancer Institute (NCI) National Institutes of Health Building 37 Room 4002 37 Convent Drive Bethesda, Maryland 20892 (301) 496-9033 kraemerk@nih.gov	Kenneth H. Kraemer, M.D. National Cancer Institute (NCI) National Institutes of Health Building 37 Room 4002 37 Convent Drive Bethesda, Maryland 20892 (301) 496-9033 kraemerk@nih.gov	NCI Referral Office National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office 1-888-NCI-1937

Clinical Trials Number:

NCT00046189

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

• Details on how to participate in a study
• Details on how to refer a patient to a study

NIH Clinical Studies Information Request

---

Contact the Office of Communications for:

• General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml

---

Contact the Department Clinical Research Informatics, (DCRI) for:

• Technical questions about Adobe Acrobat and the PDF format
• Technical questions about this web server

webmaster@cc.nih.gov